Skip to content

Voice Activated Personal Assistant for Depression Among Older Adults

Technology-Enabled Services to Support Caregivers of Older Adults With Depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06114485
Enrollment
80
Registered
2023-11-02
Start date
2023-12-04
Completion date
2026-06-30
Last updated
2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Anxiety

Brief summary

Participants will use Amazon Alexa to test a new voice-assisted program for mental health management. The participant will use this program to help with goal setting, reminders, and various other services. The participant may be supported by a caregiver, if available, or by research team member who will serve as a coach for the duration of the study to guide them with using the program. Participants will be asked to complete surveys and assessments about their experiences during the 12-week study period. Participants will be randomized into two groups: those who receive a guide to help them with utilization of the program to its fullest potential and those who do not receive that guide.

Detailed description

Older adults have often been on the fringe of benefiting from technology. However, voice-controlled intelligent personal assistants (VIPAs; e.g. Google Home, Amazon Echo), with their natural interaction style and ease of use, are a simple interface technology that may be useful to older adults with depression in the home setting. The caregiver or coach will be able to schedule and follow the interactions between the older adult and the VIPA. The VIPAs would potentially be able to provide functional, cognitive, and social stimulation as well as improve anti-depressant medication adherence through reminders to older adults. The aim is to evaluate a VIPA that was designed to deliver behavioral activation prompts to older adults with depression. Through user centered design (UCD), the investigators have adapted the model for remote support with the aid of VIPAs that provide psychoeducation, as well as features that support social, cognitive, and functional stimulation and reminders. The intervention will be 8 weeks, with a 4-week follow-up. During 8-week intervention, participants will be able to use Amazon Echo Show 8 and the study's VIPA program to set goals, reminders, and the like to help with their mood. Participants will also be asked to completed associated assessments. If caregivers are involved, they will also be asked to complete assessments.

Interventions

BEHAVIORALVIPA Treatment Program

Participants will receive and Alexa device with a behavioral activation program, along with a detailed guidebook about how to utilize the Alexa device and the VIPA program

BEHAVIORALAlexa with Guidebook

Participants will receive an Alexa device with a detailed guidebook on how to use the device.

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Randomized Controlled Trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults 65 years or older * English-speaking * Elevated depressive symptoms (PHQ-9 ≥ 10) * Have Wi-Fi access * Cognitively intact (Montreal Cognitive Assessment (MOCA) score ≥17) or Inclusion criteria: * Adults 18 years or older * English-speaking * Provide support to an older adult (65 or older) * Have access to Wi-Fi * Demonstrating capacity to consent * Cognitively intact (Montreal Cognitive Assessment (MOCA) score ≥17 if 65 years or older)

Design outcomes

Primary

MeasureTime frameDescription
Depressive symptoms12 weeksThe Patient Health Questionnaire-9 (PHQ-9) PHQ-9 measures depression symptom severity on a scale of 0-27, with higher scores indicating greater symptom severity. The PHQ-9 measures depressive symptom severity on a scale of 0-27, with higher scores indicating greater severity
Anxiety symptoms12 weeksThe Generalized Anxiety Disorder-7 (GAD-7) measures anxiety symptom severity on a scale of 0-21, with higher scores indicating greater severity

Secondary

MeasureTime frameDescription
Adherence8 weeksThe number of times the Alexa device was accessed (Usage; # communications with TES-VIPA)

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORDavid C Mohr, PhD

Northwestern University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 14, 2026